Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high‐risk cutaneous melanoma
暂无分享,去创建一个
S. Mocellin | D. Nitti | M. Lise | M. Foletto | C. Rossi | R. Scalerta | P. Pilati | P. Del Fiore | V. Chiarion | Laura Guarnieri
[1] W. Gillanders,et al. The molecular detection of micrometastatic breast cancer. , 2003, American journal of surgery.
[2] V. Rusch,et al. Detection and measurement of occult disease for the prognosis of solid tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Campana. Determination of minimal residual disease in leukaemia patients , 2003, British journal of haematology.
[4] N. Cascinelli,et al. World Health Organization experience in the treatment of melanoma. , 2003, Surgical Clinics of North America.
[5] D. Roses,et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] C. Garbe,et al. Diagnostic value and prognostic significance of protein S‐100β, melanoma‐inhibitory activity, and tyrosinase/MART‐1 reverse transcription‐polymerase chain reaction in the follow‐up of high‐risk melanoma patients , 2003, Cancer.
[7] V. Sondak,et al. Malignant melanoma: current state of primary and adjuvant treatment. , 2003, Critical reviews in oncology/hematology.
[8] P. Ascierto,et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Schmidt,et al. Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma , 2002, Melanoma research.
[10] D. Colomer,et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] F. Marincola,et al. Adjuvant immunotherapy for solid tumors: from promise to clinical application , 2002, Cancer Immunology, Immunotherapy.
[12] H. Gogas,et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon , 2002, British Journal of Cancer.
[13] R. Mansel,et al. Molecular detection of micro-metastasis in breast cancer. , 2002, Critical reviews in oncology/hematology.
[14] K. Arndt,et al. The genomics issue , 2001 .
[15] G. Tsavellas,et al. Detection and clinical significance of occult tumour cells in colorectal cancer , 2001, The British journal of surgery.
[16] N Cascinelli,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Martin F. Mihm,et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] U. Keilholz,et al. Minimal Residual Disease in Melanoma , 2001, Recent Results in Cancer Research.
[19] M. Giesing,et al. Molecular characterization of minimal residual cancer cells in patients with solid tumors. , 2001, Biomolecular engineering.
[20] A. Sober,et al. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. , 2001, Archives of dermatology.
[21] M. Edward,et al. Evaluation of the use of tyrosinase‐specific and melanA/MART‐1‐specific reverse transcriptase‐coupled–polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma , 2001, The British journal of dermatology.
[22] A. Baldi,et al. Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients. , 2000, Anticancer research.
[23] S. Mocellin,et al. Sentinel node biopsy and ultrasound scanning in cutaneous melanoma: clinical and technical considerations. , 2000, European journal of cancer.
[24] R. Elashoff,et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. , 2000, Cancer research.
[25] C. Berking,et al. Tumor markers in peripheral blood of patients with malignant melanoma: Multimarker RT-PCR versus a luminoimmunometric assay for S-100 , 1999, Archives of Dermatological Research.
[26] P. Hersey,et al. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Steinberg,et al. Heterogeneous expression of melanoma‐associated antigens and HLA‐A2 in metastatic melanoma in vivo , 1998, International journal of cancer.
[28] M. Lise,et al. The impact of ultrasound scanning in the staging and follow-up of patients with clinical stage I cutaneous melanoma. , 1997, European journal of cancer.
[29] S. Loening,et al. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells , 1996, Cancer.
[30] C. Scheibenbogen,et al. Detection of Residual Tumor Cells in Patients with Malignant Melanoma Responding to Immunotherapy , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[31] K. Pittman,et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction , 1991, The Lancet.
[32] P. Maslak. Clinical applications of molecular monitoring in leukemia. , 2003, Current hematology reports.
[33] V. Sondak,et al. Melanoma: Adjuvant therapy and other treatment options , 2003, Current treatment options in oncology.
[34] D. Morton,et al. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[35] C. Garbe,et al. Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[36] E. Thiel,et al. Nested quantitative real time PCR for detection of occult tumor cells. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[37] D. Coit,et al. Reverse transcriptase polymerase chain reaction (RT-PCR) detection of melanoma-related transcripts in the peripheral blood and bone marrow of patients with malignant melanoma. What have we learned? , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[38] S. Ugurel,et al. Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[39] A. Chambers. The metastatic process: basic research and clinical implications. , 1999, Oncology research.